U.S. markets closed

Precipio, Inc. (PRPO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.7800+0.0100 (+0.27%)
At close: 4:00PM EDT
3.7501 -0.03 (-0.79%)
After hours: 07:33PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close3.7700
Bid3.7300 x 1800
Ask3.8300 x 1200
Day's Range3.6500 - 3.8900
52 Week Range1.0500 - 9.1800
Avg. Volume14,726,353
Market Cap85.833M
Beta (5Y Monthly)2.64
PE Ratio (TTM)N/A
EPS (TTM)-0.4710
Earnings DateAug 16, 2021 - Aug 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Precipio Terminates its Equity Line

    Precipio Terminates its Equity Line

    NEW HAVEN, Conn., June 15, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces that as part of management’s review of its current financing arrangements, it has terminated the equity line financing structure it had in place with Lincoln Park Capital. The equity line was used by Precipio to fund day-to-day operations and cover its operational cash burn that was required for the Company’s continued growth. With the Company’s current situation - growing r

  • Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool

    Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool

    Laboratories can use this rapid, cost effective test to distinguish malignancy-driven anemia from other causes NEW HAVEN, Conn., June 08, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched the HemeScreen® Anemia Panel as part of its suite of diagnostic tests. The purpose of this panel is to help physicians address one of the more significant clinical challenges they face: anemia of unknown cause. Precipio’s HemeScreen Anemia Panel


    Precipio, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 20, 2021 / Precipio, Inc. (NASDAQ:PRPO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 20, 2021 at 5:00 PM Eastern Time.